top of page

Recent Posts

FDA Grants Orphan Drug Designation to Opaganib in Neuroblastoma

OPACC
Sep 13, 2024
1 min read

The FDA has granted a second orphan drug designation to opaganib in oncology, this time for patients with neuroblastoma.

Read more: https://www.targetedonc.com/view/fda-grants-orphan-drug-designation-to-opaganib-in-neuroblastoma

Comments

Nemours study points to need for more psychosocial support for childhood cancer treatment

AHA Scientific Statement on CV Toxicity in Patients Treated for Childhood Cancer

Female AYA Cancer Survivors May Benefit From Increased Physical Activity

Nutrition is a key ingredient for defense against infectious diseases in kids with cancer

Auditory Attention Decay Noted Post-Treatment in Pediatric Cerebellar Tumors

Cardiometabolic Considerations for Childhood Cancer Survivors Explained

Sex and Age May Influence Comorbidities in Pediatric ALL

FDA Grants Rare Pediatric Designation to Treatment With NEO100 in Brain Cancer

Untreated GHD Linked to Adverse Outcomes in Childhood Cancer Survivors

Trial Shows Targeted Treatment for Childhood Brain Tumor is Safe

Archive

Search By Tags

bottom of page